Emergency Preparedness and Response
Dr. Luciana Borio: Faces Behind MCMi
|I feel privileged for the opportunity to lead FDA’s MCM initiative. As you can see from our Meet MCMi webpage, the staff working on this Agency-wide effort are exceptionally qualified and extremely committed. |
This initiative is a very complex, long-term effort that will require extensive collaboration, continuous support, and a willingness to do things a little differently. I truly believe we are making a difference.
I joined FDA’s Center for Biologics Evaluation and Research in 2008 — expecting a calm, predictable work routine that would allow me to meet the needs of my young family. Then — the influenza pandemic hit, bringing me into the Office of the Commissioner to help FDA’s Chief Scientist with all of the tasks that this public health emergency entailed. Now, 4 years later, I am FDA Assistant Commissioner for Counterterrorism Policy and Director of the Office of Counterterrorism and Emerging Threats.
Our office has the responsibility, together with FDA’s medical product centers, to implement FDA’s Medical Countermeasures initiative (MCMi), launched in 2010 to support the US Public Health Emergency Medical Countermeasures Enterprise. FDA is working closely with its federal partners in the Department of Health and Human Services and with the Department of Homeland Security, the DoD, academia, regulated industry, and other relevant state and local organizations to ensure that safe and effective drugs, vaccines, detection devices, and other equipment are readily available, should we face another emerging infectious disease threat, like the flu pandemic, or an event involving a chemical, biological, radiological, or nuclear agent.
Prior to joining FDA’s Center for Biologics Evaluation and Research in 2008, Dr. Borio was Senior Associate at the Center for Biosecurity of UPMC and Assistant Professor of Medicine at the University of Pittsburgh (2003-2008). Dr. Borio served at the U.S. Department of Health and Human Services (HHS) as an Advisor on Biodefense Programs (2001 to 2008), where she implemented and managed mathematical modeling projects to assess the health effects of bioterrorism on civilians and to inform medical countermeasures procurement activities for the Office of Preparedness and Response.
Dr. Borio is a member of the Infectious Diseases Society of America, where she serves on their Pandemic Influenza Task Force. After receiving her MD from the George Washington University, Dr. Borio completed her residency in internal medicine at the New York Presbyterian Hospital - Cornell Medical Center and subsequently completed a combined fellowship in infectious diseases (at Johns Hopkins University) and critical care medicine (at the National Institutes of Health). Dr. Borio continues to practice medicine at Johns Hopkins Hospital.